Right Ventricle Dysfunction in PAH May Be Treated by Drug Targeting a Signaling Pathway Independent of Arterial Pressure

By MAGDALENA KEGEL Blocking the enzyme sphingosine kinase 1 (SK1) reduced right ventricle enlargement in a mouse model of pulmonary arterial hypertension (PAH), while having no impact on blood vessel remodeling. The findings, published in the journalCellular Signalling, highlighted disease...

Researchers Identify 2 Possible Blood Biomarkers of PAH Progression and Severity

By Patricia Inacio, PhD Galectin-3 (Gal-3) and the hormone aldosterone are two potentialbiomarkers for disease progression in patients with pulmonary arterial hypertension, according to a recent study, “Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension,” published in the journal...